Effects of polymorphisms of chemokine receptors on neurodevelopment and the onset of encephalopathy in children with perinatal HIV-1 infection

Antolin Llorente, Pim Brouwers, Bruce Thompson, Irene Cheng, Carol Macmillan, Phillip LaRussa, Lynne Mofenson, Ileana Blasini, Cynthia Chase

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This study examined the effects of chemokine receptor polymorphisms on neurodevelopment and the onset of encephalopathy in children with perinatal HIV-1 infection. Infected children (N = 121) between the ages of 1 and 72 months were categorized into dichotomous groups (heterozygous or homozygous mutant vs. homozygous wild type) for each chemokine receptor 2 (CCR2) and chemokine receptor 5 (CCR5) allele. Neurodevelopmental measures included the Bayley Scales of Infant Development (BSID) for children age ≤ 30 months and the McCarthy Scales of Children's Abilities (MSCA) for children aged > 30 months. A basic linear spline was used to model the mean value at each visit for the relevant test index, with determination of the slope between 4-12 months, 12-30 months, and 31-72 months of age. A mixed model analysis of variance was used to compare differences between slopes (Δβ) and intercepts (Δα) according to the presence or absence of the specified CCR2 or CCR5 polymorphism. Survival analyses were used to compare the onset of encephalopathy by chemokine receptor allelic grouping. After adjusting for potential confounds, statistically significant differences emerged in CCR5-39353, 39356, and 39402. Although the protective effects appeared to be discrete and transient, children with mutant CCR5 genotypes exhibited better neurodevelopmental outcomes than children with the wild type alleles. Chemokine polymorphisms did not appear to impact the onset of encephalopathy. Although possibly a temporary effect, HIV-1 infected children with selected mutant chemokine receptor polymorphims CCR5-39353, 39356, and 39402 may exhibit better neurodevelopmental outcome than children with the wild type allele.

Original languageEnglish (US)
Pages (from-to)180-189
Number of pages10
JournalApplied Neuropsychology
Volume13
Issue number3
DOIs
StatePublished - Dec 20 2006

Fingerprint

Chemokine Receptors
Brain Diseases
HIV Infections
HIV-1
CCR2 Receptors
Alleles
Onset
Polymorphism
Infection
AIDS/HIV
Aptitude
Survival Analysis
Child Development
Chemokines
Analysis of Variance
Genotype

All Science Journal Classification (ASJC) codes

  • Neuropsychology and Physiological Psychology
  • Developmental and Educational Psychology
  • Arts and Humanities (miscellaneous)

Cite this

Llorente, Antolin ; Brouwers, Pim ; Thompson, Bruce ; Cheng, Irene ; Macmillan, Carol ; LaRussa, Phillip ; Mofenson, Lynne ; Blasini, Ileana ; Chase, Cynthia. / Effects of polymorphisms of chemokine receptors on neurodevelopment and the onset of encephalopathy in children with perinatal HIV-1 infection. In: Applied Neuropsychology. 2006 ; Vol. 13, No. 3. pp. 180-189.
@article{91bdc1fd05a34e59998d583502220440,
title = "Effects of polymorphisms of chemokine receptors on neurodevelopment and the onset of encephalopathy in children with perinatal HIV-1 infection",
abstract = "This study examined the effects of chemokine receptor polymorphisms on neurodevelopment and the onset of encephalopathy in children with perinatal HIV-1 infection. Infected children (N = 121) between the ages of 1 and 72 months were categorized into dichotomous groups (heterozygous or homozygous mutant vs. homozygous wild type) for each chemokine receptor 2 (CCR2) and chemokine receptor 5 (CCR5) allele. Neurodevelopmental measures included the Bayley Scales of Infant Development (BSID) for children age ≤ 30 months and the McCarthy Scales of Children's Abilities (MSCA) for children aged > 30 months. A basic linear spline was used to model the mean value at each visit for the relevant test index, with determination of the slope between 4-12 months, 12-30 months, and 31-72 months of age. A mixed model analysis of variance was used to compare differences between slopes (Δβ) and intercepts (Δα) according to the presence or absence of the specified CCR2 or CCR5 polymorphism. Survival analyses were used to compare the onset of encephalopathy by chemokine receptor allelic grouping. After adjusting for potential confounds, statistically significant differences emerged in CCR5-39353, 39356, and 39402. Although the protective effects appeared to be discrete and transient, children with mutant CCR5 genotypes exhibited better neurodevelopmental outcomes than children with the wild type alleles. Chemokine polymorphisms did not appear to impact the onset of encephalopathy. Although possibly a temporary effect, HIV-1 infected children with selected mutant chemokine receptor polymorphims CCR5-39353, 39356, and 39402 may exhibit better neurodevelopmental outcome than children with the wild type allele.",
author = "Antolin Llorente and Pim Brouwers and Bruce Thompson and Irene Cheng and Carol Macmillan and Phillip LaRussa and Lynne Mofenson and Ileana Blasini and Cynthia Chase",
year = "2006",
month = "12",
day = "20",
doi = "10.1207/s15324826an1303_6",
language = "English (US)",
volume = "13",
pages = "180--189",
journal = "Applied neuropsychology. Adult",
issn = "2327-9095",
publisher = "Taylor and Francis",
number = "3",

}

Effects of polymorphisms of chemokine receptors on neurodevelopment and the onset of encephalopathy in children with perinatal HIV-1 infection. / Llorente, Antolin; Brouwers, Pim; Thompson, Bruce; Cheng, Irene; Macmillan, Carol; LaRussa, Phillip; Mofenson, Lynne; Blasini, Ileana; Chase, Cynthia.

In: Applied Neuropsychology, Vol. 13, No. 3, 20.12.2006, p. 180-189.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of polymorphisms of chemokine receptors on neurodevelopment and the onset of encephalopathy in children with perinatal HIV-1 infection

AU - Llorente, Antolin

AU - Brouwers, Pim

AU - Thompson, Bruce

AU - Cheng, Irene

AU - Macmillan, Carol

AU - LaRussa, Phillip

AU - Mofenson, Lynne

AU - Blasini, Ileana

AU - Chase, Cynthia

PY - 2006/12/20

Y1 - 2006/12/20

N2 - This study examined the effects of chemokine receptor polymorphisms on neurodevelopment and the onset of encephalopathy in children with perinatal HIV-1 infection. Infected children (N = 121) between the ages of 1 and 72 months were categorized into dichotomous groups (heterozygous or homozygous mutant vs. homozygous wild type) for each chemokine receptor 2 (CCR2) and chemokine receptor 5 (CCR5) allele. Neurodevelopmental measures included the Bayley Scales of Infant Development (BSID) for children age ≤ 30 months and the McCarthy Scales of Children's Abilities (MSCA) for children aged > 30 months. A basic linear spline was used to model the mean value at each visit for the relevant test index, with determination of the slope between 4-12 months, 12-30 months, and 31-72 months of age. A mixed model analysis of variance was used to compare differences between slopes (Δβ) and intercepts (Δα) according to the presence or absence of the specified CCR2 or CCR5 polymorphism. Survival analyses were used to compare the onset of encephalopathy by chemokine receptor allelic grouping. After adjusting for potential confounds, statistically significant differences emerged in CCR5-39353, 39356, and 39402. Although the protective effects appeared to be discrete and transient, children with mutant CCR5 genotypes exhibited better neurodevelopmental outcomes than children with the wild type alleles. Chemokine polymorphisms did not appear to impact the onset of encephalopathy. Although possibly a temporary effect, HIV-1 infected children with selected mutant chemokine receptor polymorphims CCR5-39353, 39356, and 39402 may exhibit better neurodevelopmental outcome than children with the wild type allele.

AB - This study examined the effects of chemokine receptor polymorphisms on neurodevelopment and the onset of encephalopathy in children with perinatal HIV-1 infection. Infected children (N = 121) between the ages of 1 and 72 months were categorized into dichotomous groups (heterozygous or homozygous mutant vs. homozygous wild type) for each chemokine receptor 2 (CCR2) and chemokine receptor 5 (CCR5) allele. Neurodevelopmental measures included the Bayley Scales of Infant Development (BSID) for children age ≤ 30 months and the McCarthy Scales of Children's Abilities (MSCA) for children aged > 30 months. A basic linear spline was used to model the mean value at each visit for the relevant test index, with determination of the slope between 4-12 months, 12-30 months, and 31-72 months of age. A mixed model analysis of variance was used to compare differences between slopes (Δβ) and intercepts (Δα) according to the presence or absence of the specified CCR2 or CCR5 polymorphism. Survival analyses were used to compare the onset of encephalopathy by chemokine receptor allelic grouping. After adjusting for potential confounds, statistically significant differences emerged in CCR5-39353, 39356, and 39402. Although the protective effects appeared to be discrete and transient, children with mutant CCR5 genotypes exhibited better neurodevelopmental outcomes than children with the wild type alleles. Chemokine polymorphisms did not appear to impact the onset of encephalopathy. Although possibly a temporary effect, HIV-1 infected children with selected mutant chemokine receptor polymorphims CCR5-39353, 39356, and 39402 may exhibit better neurodevelopmental outcome than children with the wild type allele.

UR - http://www.scopus.com/inward/record.url?scp=33845487157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845487157&partnerID=8YFLogxK

U2 - 10.1207/s15324826an1303_6

DO - 10.1207/s15324826an1303_6

M3 - Article

C2 - 17361671

AN - SCOPUS:33845487157

VL - 13

SP - 180

EP - 189

JO - Applied neuropsychology. Adult

JF - Applied neuropsychology. Adult

SN - 2327-9095

IS - 3

ER -